Syros Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Conley Chee

İcra Kurulu Başkanı

US$1.0m

Toplam tazminat

CEO maaş yüzdesi	46.0%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	11.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Conley Chee'un ücretlendirmesi Syros Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

Tazminat ve Piyasa: Conley 'nin toplam tazminatı ($USD 1.04M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 353.74K ).

Tazminat ve Kazançlar: Conley şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Conley Chee (54 yo)

less than a year

Görev süresi

US$1,041,697

Tazminat

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Conley Chee	CEO, President & Director	less than a year	US$1.04m	Veri yok
Richard Young	Scientific Founder & Member of Scientific Advisory Board	no data	US$82.15k	0.040% $ 2.7k
Jason Haas	Chief Financial Officer	3.1yrs	US$833.02k	0% $ 0
David Roth	Chief Medical Officer	8.9yrs	US$876.53k	0% $ 0
James Bradner	Founder	no data	Veri yok	Veri yok
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	2.1yrs	US$1.46m	0% $ 0
Lisa Roberts	Vice President of Human Resources	1.8yrs	Veri yok	Veri yok
Kristin Stephens	Chief Development Officer	4.4yrs	Veri yok	0% $ 0

2.6yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 0LC7 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Conley Chee	CEO, President & Director	less than a year	US$1.04m	Veri yok
Richard Young	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	US$82.15k	0.040% $ 2.7k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok
Peter Karl Wirth	Independent Chairman	7.8yrs	US$110.40k	0.060% $ 4.0k
Mark Murcko	Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok
Marsha Fanucci	Independent Director	9.1yrs	US$84.78k	0.060% $ 4.0k
Nancy Simonian	Director	11.6yrs	US$1.49m	0.66% $ 44.1k
Gerard Evan	Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok
Scott Biller	Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok
Bradley Bernstein	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stefan Knapp	Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok
Aviv Regev	Member of Scientific Advisory Board	11.6yrs	Veri yok	Veri yok

11.6yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0LC7 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.6 yıldır).

Syros Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Financial Officer recently bought US$161k worth of stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Insufficient new directors

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought US$161k worth of stock

New minor risk - Market cap size

New minor risk - Profitability

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Insufficient new directors

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Insufficient new directors

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Insufficient new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Insufficient new directors

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations